LivaNova

In this article, the impact that LivaNova has had on different aspects of society will be addressed. Since its emergence, LivaNova has aroused the interest of researchers, academics, specialists and the general public, due to its relevance in various areas. The influence of LivaNova on culture, economy, technology, politics, among other aspects, will be explored with the aim of understanding its role in shaping the current world. In addition, it will be analyzed how LivaNova has transformed the way people interact with each other and how they operate in their environment. Through this article, we aim to provide a comprehensive view of LivaNova, allowing the reader to obtain a broader and clearer perspective on its impact and significance.

LivaNova, PLC
Company typePublic
Nasdaq: LIVN
S&P 400 Component
ISINGB00BYMT0J19
IndustryMedical Devices
Founded1987 (1987)
Headquarters
  • Legal headquarters: 20 Eastbourne Terrace, London
  • Operational headquarters, North America): 100 Cyberonics Blvd Ste 600, Houston, Texas
Key people
  • Vladimir Makatsaria (CEO)
  • Alex Shvartsburg (CFO)
ProductsMedical devices for neuromodulation and cardiac surgery
Number of employees
2,900
Websitewww.livanova.com

LivaNova, PLC is an Italian-American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".

History

In 1956, Sorin Biomedica was founded by Italy's two largest industrial groups at that time: Fiat and Montedison (now under Edison). The name 'Sorin' is an acronym for Società Ricerche Impianti Nucleari (Company for Nuclear Plant Research). Later the company became known as Sorin Group.

In 1987, Cyberonics, Inc. was founded in Houston, United States.

In March 2015, the two companies announced they would be merging in a $2.7B transaction. The transaction closed and the company began trading under the new stock symbol on Oct. 19. 2015. In December 2017, LivaNova announced it would acquire Imthera Medical for approximately $224M.

In 2018, LivaNova sold its cardiac rhythm management business unit to MicroPort for $190M.

In 2020, LivaNova announced the sale of its heart valve (HV) business

In May 2022, Livanova announced the acquisition of Pittsburgh based biotechnology company ALung Technologies Inc. LivaNova PLC will acquire the 97% interest in privately held ALung that it doesn’t currently own for the $10 million deal.

In April 2023, CEO Damien McDonald resigned.

On March 1, 2024, Vladimir Makatsaria was appointed LivaNova's new CEO and Board Director.

Business units

The new combined company announced in May 2015 that it was focused on three product categories and will operate as three business units. The three units are: neuromodulation, with its operating HQ in Houston; cardiac surgery, with its operating HQ in Italy; cardiac rhythm management, with its operating HQ in France.

In 2018, the cardiac rhythm management business unit was sold to focus on the remaining two.

In March 2020, LivaNova established Epsy Health, a digital health unit aimed at empowering patients, caregivers and healthcare providers in their journey for the treatment of epilepsy.

In December 2020, LivaNova announced the disposal of its heart valve (HV) business.

LivaNova provides vagus nerve stimulation products.

References

  1. ^ "Company about page".
  2. ^ a b "Merged Houston company begins trading under new name". Houston Business Journal. 19 October 2015. Retrieved 19 October 2015.
  3. ^ "From Fiat to heart valves". INSEAD. 26 April 2012. Retrieved 19 October 2015.
  4. ^ "Houston's Top Workplaces - 2012" (PDF). Houston Chronicle. 11 November 2012. Retrieved 19 October 2015.
  5. ^ a b "Deal of the Week: Houston's Cyberonics teams up with Italian firm for $2.7B". Houston Chronicle. 6 May 2015. Retrieved 19 October 2015.
  6. ^ "BRIEF-Livanova To Acquire Imthera Medical". Reuters. 5 December 2017. Retrieved 5 December 2017.
  7. ^ a b "LivaNova closes $190 CRM sale to MicroPort". Mass Device. 30 April 2018.
  8. ^ "LivaNova reaches agreement to sell its heart valve business". Cardiovascular News. 3 December 2020.
  9. ^ "London-based LivaNova is picking up another Pittsburgh biotech firm". Pittsburgh Post-Gazette. 6 May 2022. Retrieved 9 May 2022.
  10. ^ Peter Green (17 April 2023). "LivaNova CEO quits as firm announces higher-than-expected preliminary earnings". MedTech Dive.
  11. ^ "LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director". MedTech Dive. 1 March 2024.
  12. ^ "LivaNova 2021 UK Annual Report". Retrieved 28 March 2023.
  13. ^ Conor Hale (3 December 2020). "LivaNova to exit heart valve business via €60M carve-out deal". Fierce Biotech.
  14. ^ "Therapeutic Areas for the Head and Heart | LivaNova". www.livanova.com. Retrieved 16 November 2023.
  15. ^ Reif-Leonhard, C.; Reif, A.; Baune, B. T.; Kavakbasi, E. (1 September 2022). "Vagusnervstimulation bei schwer zu behandelnden Depressionen". Der Nervenarzt (in German). 93 (9): 921–930. doi:10.1007/s00115-022-01282-6. ISSN 1433-0407. PMC 9452433. PMID 35380222.

External links

  • Business data for LivaNova:
Wikious
Boobota
Sagapedia